Bringing together researchers from Italy and the US, Chroma Medicine has emerged out of stealth with series A financing led by Cormorant Asset Management.

Chroma Medicine, a US-based epigenetic editing technology developer exploiting research from multiple institutions, has launched with $125m in series A financing led by hedge fund Cormorant Asset Management. Casdin Capital, Janus Henderson Investors, Omega Funds, funds and accounts advised by T Rowe Price Associates, Wellington Management, Atlas Venture, Newpath Partners and Sofinnova Partners all backed…

The rest of this content is only accessible to Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.